BioCentury
ARTICLE | Clinical News

TTP488: SPA received

July 28, 2014 7:00 AM UTC

TransTech said it received an SPA from FDA for a double-blind, placebo-controlled Phase III trial to evaluate 5 mg oral TTP488 once daily for 18 months in about 800 patients with mild AD receiving standard of care (SOC). The company expects to start the trial by year end. TTP488 has Fast Track designation In the U.S. to treat AD. ...